p53 biology and reactivation for improved therapy in MDS and AML.

A clear trend was observed for increases in serum GDF-15 (growth/differentiation factor-15), a biomarker for p53 transcription activity.

also in 19,460 other papers

At a median follow-up of 12 months, Aprea Therapeutics, the study sponsor, reported that the CR rate was 37% higher in eprenetapopt with AZA arm compared to AZA alone but did not reach statistical significance and the study failed to meet the primary endpoint [ 98 , 99 ].

also in 111,027 other papers